Roche touts upbeat PhII results for heart drug

Roche ($RHHBY) is reporting encouraging results from a mid-stage study of inclacumab, saying the data demonstrated a clear clinical benefit by reducing inflammation during angioplasty.  Investigators tracked patients' response to the drug, comparing its effect on key biomarkers with a placebo. "It was exciting to see that a single administration of inclacumab would yield clinical benefit," Dr. Jean-Claude Tardif told Reuters at the American College of Cardiology scientific meeting in San Francisco. "This is huge potentially. A drug that blocks the inflammatory process on top of statins holds a lot of potential." Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.